Real-world nausea/vomiting control during anticancer therapy: a cross-sectional survey
Supportive Care in Cancer · 2026-11 · 34 (11)
DOI: 10.1007/s00520-026-11374-7 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Supportive Care in Cancer, online erschienen am 24.10.2026. Verfasst von Wanqiu Peng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Zhongshan Hospital, Fudan University, Shanghai, 200032, China. Hauptthemen laut MEDLINE: Nausea, Antiemetics, Vomiting, Antineoplastic Agents. Die Arbeit nennt 15 Literaturangaben. Gefördert von: Fudan University Clinical Research Management Soft Science Project, Clinical Research Special Project of Zhongshan Hospital, Fudan University.
Abstract (Originalsprache)
Purpose
To characterize real-world antiemetic prescribing, nausea/vomiting control, and implementation gaps in supportive care during anticancer therapy.
Methods
We analyzed 624 anonymized physician-completed questionnaire records. Anticancer regimens were mapped to NCCN Antiemesis Version 2.2023 emetic-risk categories using the highest-risk principle. Because dose, agent, timing, and delayed-phase continuation were not uniformly captured, guideline implementation was assessed using prespecified medication-class proxies based on the first antiemetic regimen.
Results
High- and moderate-emetic-risk regimens accounted for 389/624 (62.3%) and 150/624 (24.0%) records, respectively. Acute nausea (330/624, 52.9%) and delayed nausea (238/624, 38.1%) were more common than vomiting. Residual nausea persisted in 143/624 (22.9%) records after antiemetic treatment. Initial regimens were predominantly 5-HT_3 receptor antagonist-based (555/624, 88.9%). Among HEC/MEC-classifiable records, the core class-level concordance was met in 188/539 (34.9%), and the four-class documentation proxy for HEC was observed in only 8/389 (2.1%). In multivariable analysis, meeting the core proxy was not significantly associated with fewer residual symptoms (adjusted OR, 1.40; 95% CI, 0.88–2.23), whereas prior CINV was independently associated with residual symptoms (adjusted OR, 2.53; 95% CI, 1.53–4.18).
Conclusion
Antiemetic use was common, yet nausea, particularly delayed and residual nausea, remained frequent, and risk-adapted multidrug prophylaxis for high-risk therapy was incompletely implemented. Improving care will require separate assessment of nausea, appropriate prophylaxis throughout the emetic-risk window, and reassessment across treatment cycles that considers prior CINV, tolerability, adherence, and affordability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
- Zhongshan Hospital, Fudan University, Shanghai, 200032, China. wang.hao@zs-hospital.sh.cn.
- Eye & ENT Hospital, Fudan University, Shanghai, 200031, China. hechangding@163.com.
Förderung
- Fudan University Clinical Research Management Soft Science Project
- Clinical Research Special Project of Zhongshan Hospital, Fudan University
Zitieren
APA
Peng, W., Wang, H., & He, C. (2026). Real-world nausea/vomiting control during anticancer therapy: a cross-sectional survey. Supportive Care in Cancer, 34(11). https://doi.org/10.1007/s00520-026-11374-7
Vancouver
Peng W, Wang H, He C. Real-world nausea/vomiting control during anticancer therapy: a cross-sectional survey. Supportive Care in Cancer. 2026;34(11). doi:10.1007/s00520-026-11374-7
BibTeX
@article{Peng2026,
author = {Peng, Wanqiu and Wang, Hao and He, Changding},
title = {Real-world nausea/vomiting control during anticancer therapy: a cross-sectional survey},
journal = {Supportive Care in Cancer},
year = {2026},
volume = {34},
number = {11},
doi = {10.1007/s00520-026-11374-7}
}
EUVIMED